{
    "clinical_study": {
        "@rank": "164883", 
        "arm_group": [
            {
                "arm_group_label": "Fractional carbon dioxide laser", 
                "arm_group_type": "Experimental", 
                "description": "Single session of fractional laser is done using DEKA machine , for 3 months ."
            }, 
            {
                "arm_group_label": "Ultraviolet A1 phototherapy (UVA1)", 
                "arm_group_type": "Active Comparator", 
                "description": "24 sessions of UVA 1 phototherapy are give at a rate of 3 sessions per week , at a dose of 30 joules using a Waldman targeted machine."
            }
        ], 
        "brief_summary": {
            "textblock": "The study aims at evaluating the efficacy of the fractional carbon dioxide laser as a new\n      modality for treatment of localized scleroderma and to compare its results with the well\n      established method of UVA 1 phototherapy."
        }, 
        "brief_title": "Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Localized Scleroderma", 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Scleroderma, Localized"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study includes 20 Cases presenting with one or more lesions of morphea (plaque, linear\n      and atrophic). Each case will be subjected to:\n\n        1. -Informed consent. 2-Detailed history 3- Clinical examination to assess type, site,\n           extent. 4-Clinical evaluation before treatment, in the follow  up period  and after\n           treatment ( 24 sessions of UVA1)  (one month after last CO2 laser session) using a\n           scoring system:\n\n             -  Skin thickness:   0-3, 0: normal; 1: thickened skin; 2: decreased ability to move\n                the skin; 3: unable to pinch or move skin (according to the Modified Rodnan skin\n                score)\n\n             -  Dermal atrophy: 0-3, 0: none, 1: shiny, 2: visible vessels, 3: obvious atrophy\n\n             -  Dyspigmentation (Hypo or hyper pigmentation): 0-3, 0:  none, 1: mild, 2: moderate\n                ,3: marked C- Digital Photography before, follow up and after treatment using the\n                same digital camera , at fixed distance  and constant settings for standardization\n                .\n\n                5-Investigations: A- Punch biopsy: A punch biopsy will be taken before and after\n                treatment to be stained with haematoxylin and eosin.\n\n      B-Immunohistochemical assessment of\n\n        -  MMP1 (matrix metalloproteinase 1) in the pre and post treatment skin biopsies.\n\n        -  TGF\u00df ( transforming growth factor beta)in the pre and post treatment skin biopsies.\n\n           6-Treatment intervention: Two lesions with identical scoring will be chosen for the\n           treatment interventions.\n\n             1. Lesion number (1) will be subjected to: localized UVA1 phototherapy (340-400 nm),\n                low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with\n                full clinical evaluation and investigations before and after treatment and\n                clinical follow up one month after treatment.\n\n             2. Lesion  number (2) will be subjected to: Fractional carbon dioxide laser (10,600\n                nm), a session once per month, total of 3 sessions with full clinical evaluation\n                and investigations before and one month after the last session of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Types of morphea: plaque, linear and atrophic.\n\n          2. Patients are either new or discontinued systemic treatment for at least two months\n\n        Exclusion Criteria:\n\n          1. Morphea profunda and  systemic scleroderma (diagnosed by: Rayaund's Phenomenon and\n             sclerodactyly +/- internal organ affection)\n\n          2. Contraindications to phototherapy: eg: photosensitivity, systemic lupus, melanoma,\n             skin cancer, or porphyria.\n\n          3. Contraindications to laser: Use of systemic retinoids in the last 6 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002897", 
            "org_study_id": "DDCU-24684"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fractional carbon dioxide laser", 
                "description": "Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.", 
                "intervention_name": "Fractional carbon dioxide laser", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Ultraviolet A1 phototherapy (UVA1)", 
                "description": "localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.", 
                "intervention_name": "Ultraviolet A1 phototherapy (UVA1)", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Localized scleroderma UVA1 fractional carbon dioxide laser", 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "contact": {
                "email": "suzanshalaby@kasralainy.edu.eg", 
                "last_name": "Suzan M Shalaby, Ass.lecturer", 
                "phone": "01224019459"
            }, 
            "contact_backup": {
                "email": "manal.bosseila@kasralainy.edu.eg", 
                "last_name": "Manal AW Bosseila, Professor", 
                "phone": "01002412964"
            }, 
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt", 
                    "zip": "020"
                }, 
                "name": "Cairo University- Dermatology outpatient clinic"
            }, 
            "investigator": {
                "last_name": "Suzan M Shalaby, Ass.lecturer", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Fractional Carbon Dioxide Laser Versus UVA1 Phototherapy for Treatment of Localized Scleroderma: A Clinical & Immunohistochemical Comparative Study", 
        "other_outcome": {
            "description": "check list for each of common  complications of Laser therapy & photo therapy is done for each patient.", 
            "measure": "Assessing the complications of each type of therapy", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "overall_contact": {
            "email": "suzanshalaby@kasralainy.edu.eg", 
            "last_name": "Suzan M Shalaby, Ass.lecturer", 
            "phone": "01224019459"
        }, 
        "overall_contact_backup": {
            "email": "manal.bosseila@kasralainy.edu.eg", 
            "last_name": "Manal AW Bosseila, Professor", 
            "phone": "01002412964"
        }, 
        "overall_official": {
            "affiliation": "Cairo University", 
            "last_name": "Suzan M Shalaby, Ass.lecturer", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy will be evaluated by clinical assessment by blinded physician , biopsy before and after treatment for collagen assessment , Ultrasound bio-microscopy before and after treatment and patient satisfaction scores .", 
            "measure": "Evaluation of the efficacy of fractional carbon dioxide laser as a new method for treatment of localized scleroderma", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "reference": {
            "PMID": "22006130", 
            "citation": "Kineston D, Kwan JM, Uebelhoer NS, Shumaker PR. Use of a fractional ablative 10.6-\u03bcm carbon dioxide laser in the treatment of a morphea-related contracture. Arch Dermatol. 2011 Oct;147(10):1148-50. doi: 10.1001/archdermatol.2011.247."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002897"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cairo University", 
            "investigator_full_name": "Suzan Shalaby", 
            "investigator_title": "Assisstant lecturer - Dermatology department - Faculty of medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Improvement will be evaluated by clinical assessment by blinded physician , biopsy before and after treatment for collagen assessment , Ultrasound bio-microscopy before and after treatment and patient satisfaction scores .", 
            "measure": "Assessing the degree of improvement of cases of localized scleroderma using each method", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "source": "Cairo University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cairo University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}